---
title: VTE
layout: diseases
author: Corbin Cox
last-updated: 2018-12-14
created: 2018-12-14
toc: true
common: false
---

# Dx

**DVT:** [Well's Score](https://www.mdcalc.com/wells-criteria-dvt)

**PE:** [PERC Rule](https://www.mdcalc.com/perc-rule-pulmonary-embolism)

# DVT Prophylaxis[^gould2012]

* Low Risk: Consider ICD or no therapy
* High bleeding risk: ICD over no therapy
* Otherwise: LMWH or UFH (low dose)

Parenteral Dosing[^lexi]
{: .caption}

| Drug         | Dose                            | Adjustments                               | Notes                 |
| ------------ | ------------------------------- | ----------------------------------------- | --------------------- |
| UFH          | 5000 Units Q8-12H               | None                                      | Higher risk of HIT    |
| Enoxaparin   | 40mg SubQ QD<br />30mg SubQ BID | CrCl &lt; 30: 30mg SubQ QD                | Low risk of HIT       |
| Fondaparinux | 2.5mg SubQ QD                   | CrCl 30-50: Caution<br />CrCl &lt; 30: CI | **Must be &ge; 50kg** |

PO Dosing[^lexi]
{: .caption}

| Drug        | Indication | Dosing                                                       | Adjustments                                                  | Notes                                                       |
| ----------- | ---------- | ------------------------------------------------------------ | ------------------------------------------------------------ | ----------------------------------------------------------- |
| Rivaroxiban | THA or TKA | 10mg QD x10-14d NTE 34d starting 6-10hr after surgery        | CrCl 30-50: Caution<br />CrCl &lt; 30: CI                    | Use longer interval for THA, shorter end for TKA            |
| Apixaban    | THA or TKA | 2.5mg BID x10-14d NTE 34d starting 12-24hr after surgery     | CrCl &lt; 30: No evidence                                    |                                                             |
| Dabigatran  | THA        | 110mg x1 dose 1-4hr after surgery OR 220mg on the first day, then 220mg QD 10-14d NTE 35d | CrCl 30-50: Consider 150mg QD instead of 220mg<br />CrCl &lt; 30: No evidence | Times close to 30d recommended<br />Watch w/ PGP inhibitors |



# DVT Tx[^kearon2016]

* At least 3mo anticoag
  * PO therapy (DOAC or warfarin) preferred if no cancer
  * LMWH preferred if cancer
  * Generally stick to 3, low-moderate bleed risk unprovoked VTE recommend extended (no scheduled stop date)
  * If DVT recurs while on anticoag, switch to LMWH or increase LMWH by 25-33% if already on LMWH
* ASA is not as good as anticoag, but better than nothing
* Distal DVT w/ serial imaging can forgo anticoag if thrombus does not extend

# PE Tx[^kearon2016]

* Low Risk: Tx outpatient
* Thrombolysis for hemodynamic instability (SBP &lt; 90) w/o high bleed risk
  * Give thrombolytics if pt deteriorates after anticoag **if low bleed risk**
  * Systemic over catheter directed
  * Hemodynamically unstable / shock, high bleed risk, or failure of systemic thrombolysis => catheter directed removal
* No thrombolysis if hemodynamically stable

# DVT/PE Tx Dosing

Initial Parenteral Anticoag[^lexi]
{: .caption}

| Drug         | Dose                                                         | Adjustments                                                  |
| ------------ | ------------------------------------------------------------ | ------------------------------------------------------------ |
| UFH          | 80 U/kg IVB then 18 U/kg/hr<br />333 U/kg SubQ then 250 U/kg Q12H | Monitor aPTT Q4-6H (titration) or Q24H (Wt based) based on protocol<br />Goal 1.5-2x ULN |
| Enoxaparin   | 1 mg/kg SubQ Q12H<br />1.5 mg/kg SubQ Q24H                   | CrCl &lt; 30: 1 mg/kg SubQ Q24H                              |
| Fondaparinux | &lt; 50kg: 5mg SubQ QD<br />50-100kg: 7.5mg SubQ QD<br />&gt; 100kg: 10mg SubQ QD<br />x5-9d | CrCl 30-50: Caution<br />CrCl &lt; 30: CI                    |

PO Anticoag[^lexi]
{: .caption}

| Drug        | Dose                                             | Notes                                                        |
| ----------- | ------------------------------------------------ | ------------------------------------------------------------ |
| Warfarin    | 2.5-7.5mg PO QD initial                          | Start w/ parenteral anticoag until therapeutic INR<br />Titrate based on INR (Goal 2-3) |
| Rivaroxaban | 15mg PO BID x21d then 20mg PO QD                 | **Must be taken w/ food**<br />No initial parenteral anticoag needed |
| Apixaban    | 10mg PO BID x7d then 5mg PO QD                   | No initial parenteral anticoag needed                        |
| Dabigatran  | 150mg PO BID                                     | Initiate after 5d of parenteral anticoagulant<br />Avoid if CrCl &le; 30 (never in trials)<br />Watch w/ PGP inhibitors |
| Edoxaban    | &gt; 60kg: 60mg PO QD<br />&le; 60kg: 30mg PO QD | Initiate after 5d of parenteral anticoagulant<br />**Do not use if CrCl &gt; 95 or &lt; 15**<br />CrCl 15-50: 30mg QD |



# Preferred Agents

Preferred Anticoagulants[^kearon2016]
{: .caption}

| Factor                       | Agent                                                |
| ---------------------------- | ---------------------------------------------------- |
| Cancer                       | LMWH                                                 |
| Parenteral Therapy CI        | Rivaroxaban or Apixaban<br />(others require bridge) |
| QD PO Therapy Preferred      | Rivaroxaban, Edoxaban, Warfarin                      |
| Liver disease / coagulopathy | LMWH                                                 |
| CrCl &lt; 30                 | Warfarin                                             |
| CAD                          | Warfarin, Rivaroxaban, Apixaban, Edoxaban            |
| Hx of GI Bleeds              | Apixaban, Warfarin                                   |
| Thrombolytic Use             | UFH Infusion                                         |
| Pregnancy                    | LMWH                                                 |


# References

[^kearon2016]: Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016;149(2):315-352. doi:[10.1016/j.chest.2015.11.026](https://doi.org/10.1016/j.chest.2015.11.026)
[^gould2012]: Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients. Chest. 2012;141(2):e227S-e277S. doi:[10.1378/chest.11-2297](https://doi.org/10.1378/chest.11-2297)
[^lexi]: Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: [http://online.lexi.com](http://online.lexi.com).